Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimerâ€™s disease psychosis, epilepsy, panic disorder and Parkinsonâ€™s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinsonâ€™s disease.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Delayed Nasdaq Other stock markets 04:00:00 01/08/2024 HKT			5-day change	1st Jan Change
44.96 ^USD	+0.74%		-.--%	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI

Market Cap	8.19B 7.19B 6.69B 6.16B 11.54B 783B 11.74B 79.42B 31.09B 388B 30.75B 30.09B 1,341B	P/E 2022	-13.6x	P/E 2023	-15.9x
Enterprise Value	7.5B 6.58B 6.13B 5.63B 10.56B 716B 10.74B 72.68B 28.45B 355B 28.14B 27.53B 1,227B	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	93.64%	Yield 2022 *	-	Yield 2023	-

05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Biotechnology Select Industry Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P Global BMI Index	CI
05/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from S&P TMI Index	CI
02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	MT
01/08/24	Cerevel Therapeutics Holdings, Inc. Announces Board Changes	CI
01/08/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from NASDAQ Composite Index	CI
01/08/24	AbbVie Inc. completed the acquisition of Cerevel Therapeutics Holdings, Inc. from FMR LLC and others.	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Dynamic Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell Midcap Growth Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) added to Russell 1000 Index	CI
01/07/24	Cerevel Therapeutics Holdings, Inc.(NasdaqCM:CERE) dropped from Russell 2000 Index	CI

02/08/24	Analyst recommendations: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
15/02/24	Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	MT
28/12/23	JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	MT
22/12/23	Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	MT
08/12/23	TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	MT

Cerevel Therapeutics Holdings, Inc. Stock

Stocks

CERE

US15678U1280

Biotechnology & Medical Research

Valuation: Cerevel Therapeutics Holdings, Inc.

Latest news : Cerevel Therapeutics Holdings, Inc.

Analysts' recommendations: Cerevel Therapeutics Holdings, Inc.

Press Releases: Cerevel Therapeutics Holdings, Inc.

News in other languages: Cerevel Therapeutics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cerevel Therapeutics Holdings, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

05/04/25	Entwistle & Cappucci LLP Files a Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, Inc.	BU
01/04/25	Entwistle & Cappucci LLP is Investigating Potential Federal Securities Law Violations in Connection with Cerevel Therapeutics Holdings, Inc. (CERE)	BU
01/08/24	AbbVie Completes Acquisition of Cerevel Therapeutics	PR
19/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease	AQ
18/04/24	Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease	AQ

02/08/24	RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Alphabet, Amazon, Lululemon, Intel, Qualcomm....
22/02/24	USA-Les valeurs à suivre à Wall Street (actualisé)
02/02/24	Omzetdaling Abbvie valt mee
13/12/23	Pharma und Gesundheit: weitere Konsolidierung
13/12/23	Farma en gezondheid: consolidatie gaat door

Manager	Title	Age	Since
John Renger CTO	Chief Tech/Sci/R&D Officer	57	01/05/2019
Matthew Calistri IRC	Investor Relations Contact	-	-
Paul Burgess PRN	Corporate Officer/Principal	53	20/06/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/8/24	Bain Capital Private Equity LP	Issuer sale	Company	65,679,781	36.0492%
1/8/24	Christopher Gordon	Issuer sale	Director	93,932	0.0516%
1/8/24	Bain Capital Private Equity LP	Issuer sale	Company	65,679,781	36.0492%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CEREVEL THERAPEUTICS HOLDINGS, INC.	+0.74%	-.--%	-.--%	+47.55%	8.19B
ARGENX SE	+0.44%	+2.24%	+50.74%	+69.67%	55.01B
WUXI APPTEC CO., LTD.	-1.32%	-2.71%	+34.27%	+77.57%	54.24B
BIONTECH SE	+0.19%	+0.87%	-16.91%	-14.92%	23.38B
INSMED INCORPORATED	+0.85%	-2.25%	-0.72%	+371.89%	22.57B
WUXI BIOLOGICS (CAYMAN) INC.	+2.07%	+1.39%	+17.20%	-10.70%	20.19B
GENMAB A/S	-1.69%	-1.75%	+27.98%	-32.63%	17.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.14%	-3.75%	+26.23%	+558.64%	15.5B
PHARMAESSENTIA CORPORATION	-6.69%	-5.11%	+169.13%	+304.89%	14.2B
EXELIXIS, INC.	-1.42%	+1.45%	+50.99%	+182.98%	14.2B
Average	-0.90%	-0.60%	+35.89%	+155.49%	24.53B
Weighted average by Cap.	-0.64%	-0.50%	+35.12%	+127.42%

	2022	2023
Net sales	-	-
Net income	-352M -308M -287M -264M -495M -33.58B -504M -3.41B -1.33B -16.65B -1.32B -1.29B -57.54B	-433M -380M -354M -325M -610M -41.35B -620M -4.2B -1.64B -20.51B -1.62B -1.59B -70.85B
Net Debt	-523M -459M -428M -393M -737M -49.99B -750M -5.07B -1.99B -24.79B -1.96B -1.92B -85.65B	-695M -610M -568M -523M -980M -66.43B -997M -6.74B -2.64B -32.95B -2.61B -2.55B -114B

3 years	19.59	44.99
5 years	19.59	46.16
10 years	9	46.16